natgillin/translations-raw huggingface dataset:
Tryk langsomt stemplet i bund, så du får tid til at synke medicinen. 
Slowly push the plunger in, allowing time to swallow.
Virkning og anvendelse Ziagen anvendes til behandling af hiv-infektioner (humant immundefektvirus). 
What Ziagen is and what it is used for Ziagen is used to treat HIV (human immunodeficiency virus) infection.
Procent med < 400 pr. ml vRNA 
Percent with <400 copies/ml vRNA
For at undgå overførsel af hiv anbefales det, at hiv-inficerede kvinder under ingen omstændigheder ammer deres børn. 
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Træk i sprøjtens stempel, indtil sprøjten indeholder den første mængde af din samlede dosis. 
Pull out the syringe plunger until the syringe contains the first part of your full dose Turn the bottle the right way up.
Disse var primært asymptomatiske hiv-inficerede patienter - Centre for Disease Control and Prevention (CDC) stadie A. De blev randomiseret til at modtage enten abacavir 600 mg én gang daglig eller 300 mg 2 gange daglig, i kombination med efavirenz og lamivudin givet én gang daglig. 
These were primarily asymptomatic HIV infected patients - Centre for Disease Control and Prevention (CDC) stage A. They were randomised to receive either abacavir 600 mg once daily or 300 mg twice daily, in combination with efavirenz and lamivudine given once daily.
Selv patienter, som ikke har genet HLA-B*5701, kan udvikle en overfølsomhedsreaktion (en alvorlig allergisk reaktion). 
Even patients who don't have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction).
Fordelen ved Ziagen er hovedsageligt baseret på resultater af studier med voksne behandlingsnaive patienter med et regime af Ziagen 300 mg 2 gange daglig i kombination med zidovudin og lamivudin. 
The demonstration of the benefit of Ziagen is mainly based on results of studies performed in adult treatment-naïve patients using a regimen of Ziagen 300 mg twice daily in combination with zidovudine and lamivudine.
Hvis du er overfølsom over for Ziagen, skal du returnere alle dine Ziagen-tabletter, så de kan blive destrueret korrekt. 
If you are hypersensitive to Ziagen, return all your unused Ziagen tablets for safe disposal.
Indlægsseddel: Information til brugeren Ziagen 20 mg/ml oral opløsning 
Package leaflet: Information for the user Ziagen 20 mg/ml oral solution
I et studie af 20 hiv-inficerede patienter der fik abacavir 300 mg 2 gange daglig, med kun én 300 mg dosis indtaget før prøveudtagning efter 24 timer, var den geometriske gennemsnitlige terminale carbovir-TP intracellulære halveringstid ved steady state 20,6 timer, sammenlignet med den geometriske gennemsnitlige abacavir plasmahalveringstid i dette studie på 2,6 timer. 
In a study of 20 HIV-infected patients receiving abacavir 300 mg twice daily, with only one 300 mg dose taken prior to the 24 hour sampling period, the geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life in this study of 2.6 hours.
Øvrige indholdsstoffer: Sorbitol 70 % (E420), saccharinnatrium, natriumcitrat, vandfri citronsyre, methylparahydroxybenzoat (E218), propylparahydroxybenzoat (E216), propylenglycol (E1520), maltodextrin, mælkesyre, glyceryltriacetat, syntetisk jordbær- og banansmag, renset vand, natriumhydroxid og/eller saltsyre til pH-justering. 
The other ingredients are sorbitol 70% (E420), saccharin sodium, sodium citrate, citric acid anhydrous, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), propylene glycol (E1520), maltodextrin, lactic acid, glyceryl triacetate, artificial strawberry and banana flavour, purified water, sodium hydroxide and/or hydrochloric acid for pH adjustment.
Indeholder blandt andet: sorbitol (340 mg/ml, E420), methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E216). 
Contains amongst others: sorbitol (340 mg/ml, E420), methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216).
Ziagen findes også som oral opløsning (20 mg abacavir/ml) til børn over tre måneder med en kropsvægt under 14 kg, eller til patienter, der har behov for en lavere dosis, eller som ikke kan synke tabletter. 
An oral solution (20 mg abacavir/ml) is also available for the treatment of children over three months of age and weighing less than 14 kg, or for people who need a lower than usual dose, or who cannot take tablets.
Autoimmune sygdomme (som f.eks. Graves´ sygdom og autoimmun hepatitis) er også blevet rapporteret i forbindelse med immunreaktivering; dog er den rapporterede tid til frembrud mere variabel, og frembrud kan forekomme mange måneder efter behandlingsstart (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Gult jernoxid. 
Iron oxide yellow
Hvis du er overfølsom over for Ziagen, skal du returnere al din Ziagen oral opløsning, så det kan blive destrueret korrekt. 
If you are hypersensitive to Ziagen, return all your unused Ziagen oral solution for safe disposal.
Plasma HIV-1-RNA <80 kopier/ml Risikodifference (én gang daglig vs. to gange daglig) 
Plasma HIV-1 RNA <80 c/ml Risk difference (once daily-twice daily)
Glaxo Operations UK Ltd. (registreret som GlaxoWellcome Operations) Harmire Road 
Glaxo Operations UK Ltd (trading as GlaxoWellcome Operations) Harmire Road
Hos voksne, behandlet med abacavir i kombination med lamivudin og zidovudin, var andelen af patienter med en udetekterbar virusbyrde (< 400 kopier/ml) ca. 70 % (”intention to treat”-analyse efter 48 uger) med et tilsvarende øget CD4-celletal. 
In adults treated with abacavir in combination with lamivudine and zidovudine the proportion of patients with undetectable viral load (<400 copies/ml) was approximately 70% (intention to treat analysis at 48 weeks) with corresponding rise in CD4 cells.
Adapteren sættes i flaskehalsen og sprøjten sættes fast i adaptoren. 
The adapter is placed in the neck of the bottle and the syringe attached to this.
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Holland 
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands
Det er vigtigt, at du tager Ziagen regelmæssigt, da der er større risiko for at få en overfølsomhedsreaktion, hvis du tager medicinen uregelmæssigt. 
It is important to take Ziagen regularly, because if you take it at irregular intervals, you may be more likely to have a hypersensitivity reaction.
Glaxo Operations UK Ltd. (registreret som GlaxoWellcome Operations), Harmire Road, Barnard Castle, Co. Durham DL12 8DT, Storbritannien eller ViiV Healthcare Trading Services UK Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irland 
Manufacturer: Glaxo Operations UK Ltd, (trading as GlaxoWellcome Operations) Harmire Road Barnard Castle Co. Durham DL12 8DT United Kingdom or ViiV Healthcare Trading Services UK Limited, 12 Riverwalk,
Ziagen indeholder også konserveringsmidler (parahydroxybenzoater), der kan udløse en overfølsomhedsreaktion (eventuelt forsinket). 
Ziagen also contains preservatives (parahydroxybenzoates) which may cause allergic reactions (possibly delayed).
Overfølsomhedsreaktioner (se også pkt. 
Hypersensitivity reactions (see also section 4.8)
Administration én gang daglig (600 mg): 
Once daily (600 mg) administration:
I cellekulturer blev abacavirs antivirale aktivitet ikke antagoniseret ved kombination med nukleosid revers transkriptasehæmmerne (NRTI'er) didanosin, emtricitabin, lamivudin, stavudin, tenofovir eller zidovudin, non-nukleosid revers transkriptasehæmmeren (NNRTI) nevirapin eller proteasehæmmeren (PI) amprenavir. 
The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.
I prækliniske toksikologiske studier blev det påvist, at behandling med abacavir øgede levervægten hos rotter og aber. 
In pre-clinical toxicology studies, abacavir treatment was shown to increase liver weights in rats and monkeys.
Metylhydroxypropylcellulose Titandioxid 
Methylhydroxypropylcellulose Titanium dioxide Polysorbate 80
Hvis du holder op med at tage Ziagen 
If you have stopped taking Ziagen
123 (74 %) ud af de 166 forsøgspersoner havde M184V/I, 50 (30 %) havde T215Y/F, 45 (27 %) havde M4IL, 30 (18 %) havde K70R og 25 (15 %) havde D67N. 
In a meta-analysis of five clinical trials where abacavir was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/I, 50 (30%) had T215Y/F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.
Ifølge kliniske studier med børn absorberes abacavir hurtigt og godt, når det gives som oral opløsning og tabletter. 
According to clinical trials performed in children abacavir is rapidly and well absorbed from oral solution and tablet formulations administered to children.
Filmovertrukne tabletter 
Film-coated Tablets
Dosisjustering af Ziagen er ikke nødvendig hos patienter med nyreinsufficiens. 
No dosage adjustment of Ziagen is necessary in patients with renal dysfunction.
Ud over bivirkninger ved Ziagen nævnt nedenfor, kan du få andre sygdomme, når du får kombinationsbehandling mod hiv. 
As well as the side effects listed below for Ziagen, other conditions can develop during combination therapy for HIV.
Ligeledes havde en større andel af børn behandlet med kombinationer, som indeholdte abacavir, HIV-1-RNA ≤ 50 kopier/ml ved 48 uger (henholdsvis 53 %, 42 % og 28 %, p=0,07). 
Similarly, greater proportions of children treated with the abacavir containing combinations had HIV-1 RNA ≤50 copies/ml at 48 weeks (53%, 42% and 28% respectively, p=0.07).
1.206 HIV-inficerede patienter i alderen 3 måneder til 17 år blev inkluderet i ARROW-studiet (COL105677); heraf fik 669 patienter abacavir og lamivudin enten som én daglig dosis eller som 2 daglige doser (se pkt. 
1206 HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the ARROW Trial (COL105677), 669 of whom received abacavir and lamivudine either once or twice daily (see section 5.1).
Ondartede tumorer opstod i forhudskirtlen hos hannerne og i clitoriskirtlen hos hunnerne hos begge arter og i leveren, urinblæren, lymfekirtler og i underhuden hos hunrotter. 
Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and the liver, urinary bladder, lymph nodes and the subcutis of females.
Ved en middelvurdering efter 144 uger blev 25 % af patienterne i behandling med ZDV/3TC/ABC/EFV og 26 % af patienterne i behandling med ZDV/3TC/EFV kategoriseret, som havende virologisk svigt. 
After a median follow-up of 144 weeks, 25% of subjects on the ZDV/3TC/ABC/EFV arm and 26% on the ZDV/3TC/EFV arm were categorised as having virological failure.
Almindelig: Udslæt (uden systemiske reaktioner) Meget sjælden: Erythema multiforme, Stevens-Johnsons syndrom og toksisk epidermal nekrolyse 
Very rare: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis
Voksne, unge og børn, der vejer mindst 25 kg: 
Adults, adolescents and children weighing at least 25 kg
Alle, der tager Ziagen, kan få en overfølsomhedsreaktion over for abacavir, der kan være livstruende, hvis de fortsætter med at tage Ziagen. 
Anyone taking Ziagen could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Ziagen.
Derimod er frekvensen af en overfølsomhedsreaktion over for abacavir rapporteret med lavere frekvens hos patienter der ikke er bærer af dette allel. 
However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.
Derfor er dosisjustering ikke nødvendig hos patienter med nedsat nyrefunktion. 
Therefore no dosage reduction is required in patients with renal impairment.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON - TABLETTER 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - TABLETS
In vivo-resistens (behandlingsnaive patienter): Isolater fra patienter, som har haft virologisk svigt under en behandling med abacavir i pivotale kliniske studier, viste i de fleste tilfælde enten ingen NRTI-relaterede ændringer i forhold til baseline (45 %) eller kun M184V- eller M1841-mutationer (45 %). 
Isolates from most patients experiencing virological failure with a regimen containing abacavir in pivotal clinical trials showed either no NRTI-related changes from baseline (45%) or only M184V or M184I selection (45%).
Vær ekstra forsigtig med at tage Ziagen 
Take special care with Ziagen
• hvis du er allergisk (overfølsom) over for abacavir (eller anden medicin, der indeholder abacavir, f.eks. Triumeq, Trizivir eller Kivexa) eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6). 
• if you are allergic (hypersensitive) to abacavir (or any other medicine containing abacavir - such as Triumeq, Trizivir or Kivexa) or any of the other ingredients of this medicine (listed in Section 6)
Uge 4 (n = 166) n Median ændring vRNA (log10 c/ml) 
Median Change vRNA (log10 c/ml)
Intracellulære farmakokinetikker 
Intracellular pharmacokinetics
Den sædvanlige dosis er 8 mg/kg 2 gange daglig eller 16 mg/kg én gang daglig, dog maksimalt en total dosis på 600 mg daglig. 
The recommended dose is 8 mg/kg twice a day or 16 mg/kg once a day, up to a maximum total daily dose of 600 mg daily.
Grunwaldzka 189, 60-322 Poznan, Polen. 
GlaxoSmithKline Pharmaceuticals S.A., ul., Grunwaldzka 189, 60-322 Poznan, Poland.
Fire eller flere NRTIforbundne mutationer 
Any two NRTIassociated mutations Any three NRTIassociated mutations Four or more NRTIassociated mutations
I et selvstændigt studie, som sammenlignede de ikke-blindede NRTI kombinationer (med og uden blindet nelfinavir) hos børn, havde en større andel af patienter behandlet med abacavir og lamivudin (71 %) eller abacavir og zidovudin (60 %) HIV-1-RNA ≤ 400 kopier/ml efter 48 uger, sammenlignet med de patienter, som blev behandlet med lamivudin og zidovudin (47 %) [p=0,09, ”intention-to-treat” analyse]. 
In a separate study comparing the unblinded NRTI combinations (with or without blinded nelfinavir) in children, a greater proportion treated with abacavir and lamivudine (71%) or abacavir and zidovudine (60%) had HIV-1 RNA ≤400 copies/ml at 48 weeks, compared with those treated with lamivudine and zidovudine (47%)[ p=0.09, intention to treat analysis].
Den orale opløsning anvendes til børn, der er over 3 måneder og som vejer under 14 kg, og til patienter hvor tabletformuleringen er uhensigtsmæssig. 
Ziagen is also available as an oral solution for use in children over three months of age and weighing less than 14 kg and for those patients for whom the tablets are inappropriate.
1.206 pædiatriske patienter i alderen 3 måneder til 17 år blev inkluderet i ARROW-studiet (COL105677) og blev doseret i henhold til vægtgruppe-anbefalingerne i WHO's behandlingsvejledning (Antiretroviral therapy of HIV infection in infants and children, 2006). 
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
Der er vedlagt et oplysningskort i pakningen med Ziagen for at gøre dig og sundhedspersonalet opmærksom på overfølsomhed over for abacavir. 
The Ziagen pack includes an Alert Card, to remind you and medical staff about abacavir hypersensitivity.
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE FLASKEETIKET - ORAL OPLØSNING 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL - ORAL SOLUTION
Mikrokrystallinsk cellulose Natriumstivelsesglycolat Magnesiumstearat Kolloid vandfri silica. 
Microcrystalline cellulose Sodium starch glycollate Magnesium stearate Colloidal anhydrous silica
Almindelig: Kvalme, opkastning, diarré Sjælden: Pancreatitis 
Gastrointestinal disorders Common: nausea, vomiting, diarrhoea Rare: pancreatitis
Abacavirs farmakokinetik er blevet undersøgt hos patienter med let nedsat leverfunktion (Child-Pugh score 5-6), der fik en enkelt dosis på 600 mg; den mediane (interval) AUC var 24,1 (10,4 - 54,8) mikrog∙time/ml. 
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose ; the median (range) AUC value was 24.1 (10.4 to 54.8) ug.h/ml.
måneder til 17 år blev inkluderet i ARROW-studiet (COL105677) og blev doseret i henhold til vægtgruppe-anbefalingerne i WHO's behandlingsvejledning (Antiretroviral therapy of HIV infection in infants and children, 2006). 
(COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
Må ikke opbevares ved temperaturer over 30 °C 
Do not store above 30°C
I et ”crossoverstudie” med 27 hiv-inficerede patienter fandt man en højere intracellulær eksponering af carbovir-TP ved behandling med 600 mg abacavir én gang daglig (AUC24,ss + 32 %, Cmax24,ss + 99 % og Ctrough + 18 %) sammenlignet med behandling med 300 mg 2 gange daglig. 
In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600 mg once daily regimen (AUC24,ss + 32 %, Cmax24,ss + 99 % and Ctrough + 18 %) compared to the 300 mg twice daily regimen.
I ”as treated” (AT) analysen var forskellen mellem begge behandlingsarme mere påfaldende (88 % af patienterne i abacavirgruppen, sammenlignet med 95 % af patienterne i zidovudingruppen (punktestimat for behandlingsforskel: -6,8, 95 % CI -11,8; -1,7). 
In the as treated (AT) analysis the difference between both treatment arms was more noticeable (88% of patients in the abacavir group, compared to 95% of patients in the zidovudine group (point estimate for treatment difference: -6.8, 95% CI11.8; -1.7).
K65R blev ikke fundet, og L74V og Y115F forekom sjældent 
K65R was absent and L74V and Y115F were uncommon (≤3%).
Resultaterne viste, at AUC for abacavir i gennemsnit (90 % CI) steg 1,89 gange (1,32 - 2,70), og abacavirs halveringstid steg 1,58 gange (1,222,04). 
The results showed that there was a mean (90%CI) increase of 1.89 fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life.
(~70 %), gastrointestinale symptomer (> 50 %) som f.eks. kvalme, abdominalsmerter, opkastning og diarré, generel utilpashed, træthed, og hovedpine (~50 %) og andre symptomer (~30 %) som f.eks. respiratoriske, slimhinde-, og muskuloskeletale symptomer. 
Major symptoms associated with ABC HSR are fever (~80%), rash (~70%), gastrointestinal symptoms (>50%) such as nausea, abdominal pain, vomiting, and diarrhoea, generalise malaise, fatigue, and headache (~50%) and other symptoms (~30%) such as respiratory, mucosal, and musculoskeletal symptoms.
Fordelen ved Ziagen er hovedsageligt påvist i studier med et 2 gange daglig regime hos behandlingsnaive voksne patienter i kombinationsbehandling (se pkt. 
The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy (see section 5.1).
Methylparahydroxybenzoat (E218) 1,5 mg/ml Propylparahydroxybenzoat (E216) 0,18 mg/ml Alle hjælpestoffer er anført under pkt. 
Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.18 mg/ml For the full list of excipients see section 6.1.
Hos voksne som tidligere havde modtaget begrænset antiretroviral behandling, havde tillæg af abacavir til kombineret antiretroviral behandling begrænset værdi i reduktion af virusbyrden (median for ændring 0,44 log10 kopier/ml efter 16 uger). 
In adults moderately exposed to antiretroviral therapy the addition of abacavir to combination antiretroviral therapy provided modest benefits in reducing viral load (median change 0.44 log10 copies/ml at 16 weeks).
Ved terapeutiske doser, en dosis på 300 mg 2 gange daglig, er den gennemsnitlige (CV) steady state Cmax og Cmin for abacavir cirka 3,00 µg/ml (30 %) henholdsvis 0,01 µg/ml (99 %). 
At therapeutic dosages a dosage of 300 mg twice daily, the mean (CV) steady state Cmax and Cmin of abacavir are approximately 3.00 µg/ml (30%) and 0.01 µg/ml(99%), respectively.
I ”intent-to-treat” (ITT) populationen, opnåede 70 % af patienterne i abacavirgruppen, sammenlignet med 69 % af patienterne i zidovudingruppen, et virologisk respons af plasma hiv-1-RNA ≤ 50 kopier/ml ved uge 48 (punktestimat for behandlingsforskel: 0,8, 95 % CI -6,3 - 7,9). 
In the intent-to-treat (ITT) population, 70% of patients in the abacavir group, compared to 69% of patients in the zidovudine group, achieved a virologic response of plasma HIV-1 RNA ≤50 copies/ml by Week 48 (point estimate for treatment difference: 0.8, 95% CI -6.3, 7.9).
Ziagen 300 mg filmovertrukne tabletter Abacavir 
Ziagen 300 mg film-coated tablets Abacavir
Lægemidlet må kun udleveres efter ordination på en recept udstedt af en begrænset lægegruppe (se bilag I: Produktresumé; pkt. 
Medicinal product subject to restricted medical prescription (See Annex I Summary of Product Characteristics, 4.2).
I kontrollerede kliniske studier var afvigende laboratoriefund, som havde sammenhæng med behandlingen med Ziagen, usædvanlige. 
In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon, with no differences in incidence observed between Ziagen treated patients and the control arms.
Efter dosering af 600 mg abacavir som tablet var den gennemsnitlige (CV) abacavir Cmax ca. 4,26 µg/ml (28 %) og den gennemsnitlige (CV) AUC∞ var 11,95 µg·time/ml (21 %). 
After a 600 mg abacavir tablet dose, the mean (CV) abacavir Cmax was approximately 4.26 µg/ml (28%) and the mean (CV) AUC∞ was 11.95 µg.h/ml (21%).
Almene symptomer og reaktioner på administrationsstedet Almindelig: Feber, svær udmatning, træthed 
General disorders and administration site conditions Common: fever, lethargy, fatigue
Ziagen 20 mg/ml oral opløsning Abacavir 
Ziagen 20 mg/ml oral solution Abacavir
Abacavir 8 mg/kg 2 gange daglig Geometrisk gennemsnit (95 % CI) 
Abacavir 8 mg/kg TwiceDaily Dosing Geometric Mean (95% Cl)
Børn, der vejer 14 til < 20 kg: Den anbefalede dosis er 300 mg daglig. 
Children weighing 14 to < 20 kg: The recommended dose is 300 mg daily.
In vivo-resistens (tidligere behandlede patienter): Der er påvist klinisk signifikant reduktion af følsomhed over for abacavir i kliniske isolater fra patienter med ukontrolleret virusreplikation, som tidligere er behandlet med, og nu er resistente over for, andre nukleosidinhibitorer. 
Clinically significant reduction of susceptibility to abacavir has been demonstrated in clinical isolates of patients with uncontrolled viral replication, who have been pre-treated with and are resistant to other nucleoside inhibitors.
Der er vedlagt et oplysningskort i pakningen med Ziagen for at gøre dig og sundhedspersonalet opmærksom på overfølsomhedsreaktioner over for abacavir. 
The Ziagen pack includes an Alert Card, to remind you and medical staff about hypersensitivity reactions.
Resultater indikerer, at FDC-gruppen var ikke-inferiør over for gruppen med abacavir 2 gange daglig baseret på ensartede reduktioner i hiv-1-RNA målt som det gennemsnitlige areal under kurven minus baseline (AAUCMB, henholdsvis -1,65 log10 kopier/ml versus1,83 log10 kopier/ml, 95 % CI -0,13 - 0,38). 
Results indicate that the FDC group was non-inferior to the abacavir twice daily group, based on similar reductions in HIV-1 RNA as measured by average area under the curve minus baseline (AAUCMB, -1.65 log10 copies/ml versus -1.83 log10 copies/ml respectively, 95% CI -0.13, 0.38).